Trial · NCT04896008
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to First Confirmed Morbidity or Mortality Event | Up to approximately 31 months | All randomized participants who received at least one dose of study treatment. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Up to approximately 31 months | All randomized participants who received at least one dose of study treatment. | Months | MEDIAN |
| SECONDARY | Transplant-free Survival | Up to approximately 31 months | All randomized participants who received at least one dose of study treatment. | Months | MEDIAN |
| SECONDARY | Percentage of Participants Who Experienced a Mortality Event | Up to approximately 31 months | All randomized participants who received at least one dose of study treatment. | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had REVEAL Lite 2.0 Risk Score available at both baseline and Week 24. | Scores on a scale | MEDIAN |
| SECONDARY | Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24 | Week 24 | All randomized participants who received at least one dose of study treatment, who were randomized more than 24 weeks prior to the data cutoff, and who had a REVEAL Lite 2.0 risk score \>7 at baseline. | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in NT-proBNP Levels at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had NT-proBNP levels available at both baseline and Week 24. | pg/mL | MEDIAN |
| SECONDARY | Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had mPAP available at both baseline and Week 24. | mmHg | MEDIAN |
| SECONDARY | Change From Baseline in Pulmonary Vascular Resistance (PVR) | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had PVR available at both baseline and Week 24. | Dynes*sec/cm^5 | MEDIAN |
| SECONDARY | Percentage of Participants Who Improve in WHO FC | Baseline and up to approximately 31 months | All randomized participants who received at least one dose of study treatment. | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in 6MWD at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had 6MWD available at both baseline and Week 24. | Meters | MEDIAN |
| SECONDARY | Change From Baseline in Cardiac Output (CO) at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment and who had CO available at both baseline and Week 24. | Liters/minute | MEDIAN |
| SECONDARY | Change From Baseline in European Quality of Life (EuroQoL)-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Week 24 | Baseline and Week 24 | All randomized participants who received at least one dose of study treatment, who were randomized more than 24 weeks prior to the data cutoff, and who had data available from at least one baseline and post-baseline PRO assessment. | Scores on a Scale | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04896008/outcomes